Physician profile
Nisha Pradeep
NPI 1831578392
$7,245.45
in general payments reported to CMS, 2019-2025
43 companies · $2,242 in 2025
The $2,242 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,044 · 2020: $268 · 2021: $1,023 · 2022: $489 · 2023: $456 · 2024: $1,723 · 2025: $2,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,420.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,125.28 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $574.55 | 2019-2025 | |
| Amgen INC. | $424.99 | 2021-2025 | Uplizna |
| Celgene Corporation | $396.23 | 2021-2025 | Zeposia |
| Genzyme Corporation | $395.43 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $363.09 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $310.75 | 2021 | |
| Pfizer INC. | $307.31 | 2023-2025 | |
| Genentech USA, INC. | $294.33 | 2019-2025 | Ocrevus |
| Lundbeck LLC | $282.52 | 2021-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $276.30 | 2019-2025 | Ultomiris, Soliris |
| Ucb, INC. | $272.60 | 2019-2025 | Rystiggo, Zilbrysq |
| Allergan, INC. | $227.21 | 2019-2022 | |
| Biogen, INC. | $206.08 | 2019-2025 | Tysabri, Vumerity |
| Acadia Pharmaceuticals INC | $205.10 | 2019-2025 | Nuplazid |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $171.65 | 2020-2025 | Emgality, Kisunla, Reyvow |
| Csl Behring | $103.41 | 2020-2025 | Hizentra |
| Ge Healthcare | $96.59 | 2019-2025 | |
| Emd Serono, INC. | $93.33 | 2021-2023 | Mavenclad |
| E.R. Squibb & Sons, L.L.C. | $86.91 | 2024 | Zeposia |
| Tg Therapeutics, INC. | $78.20 | 2025 | |
| Avanir Pharmaceuticals, INC. | $75.81 | 2019-2022 | |
| Merz Pharmaceuticals, LLC | $68.73 | 2024-2025 | Xeomin, Ampyra, Inbrija |
| Acorda Therapeutics, INC | $68.34 | 2021-2024 | Ampyra, Inbrija |
| Neurocrine Biosciences, INC. | $66.23 | 2025 | |
| Amneal Pharmaceuticals LLC | $62.10 | 2019-2024 | Crexont, Rytary |
| Takeda Pharmaceuticals U.S.A., INC. | $58.66 | 2025 | Hyqvia |
| Eisai INC. | $53.75 | 2024-2025 | |
| Argenx US, INC. | $53.67 | 2024-2025 | Vyvgart Hytrulo |
| Janssen Pharmaceuticals, INC | $50.43 | 2022-2024 | Spravato |
| Alnylam Pharmaceuticals INC. | $44.66 | 2022-2023 | Onpattro |
| Azurity Pharmaceuticals, INC. | $42.21 | 2024 | Horizant |
| Greenwich Biosciences, INC. | $41.11 | 2019 | |
| Impel Pharmaceuticals LLC | $36.94 | 2025 | Trudhesa |
| Aquestive Therapeutics, INC. | $35.88 | 2019 | |
| Sk Life Science, INC. | $31.92 | 2025 | |
| Janssen Biotech, INC. | $29.70 | 2025 | |
| Nevro Corp. | $26.20 | 2022 | |
| Horizon Therapeutics Plc | $23.68 | 2023 | Uplizna |
| Vanda Pharmaceuticals INC. | $23.60 | 2024 | Ponvory |
| Sanofi-Aventis U.S. LLC | $22.36 | 2021 | |
| Livanova USA, INC. | $19.04 | 2019 | |
| Grifols USA, LLC | $18.57 | 2025 | Gamunex-C |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Pradeep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.